Longeveron reports DMC approval for laromestrocel study to continue as designed

Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating laromestrocel as a potential adjunct therapy for hypoplastic left heart syndrome. The DMC based its review on available data for all participating patients enrolled. The DMC performed a risk-benefit assessment, indicated no safety concerns, and approved the study to continue as designed to completion. ELPIS II enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the country.